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Background: Clinical trials are increasingly being conducted as new products seek to enter the market.
Deployment of such interventions is based on evidence obtained mainly from the gold standard of randomized
controlled clinical trials (RCCT). A crucial factor in the ability of RCCTs to provide credible and generalisable data is
sample size and retention of the required number of subjects at completion of the follow-up period. However,
recruitment and retention in clinical trials are hindered by prevalent peculiar challenges in Africa that need to be
circumvented. This article shares experiences from a phase II trial that recorded a high retention rate at 14 months
follow-up at a new clinical trial site.
Methods: Mothers bringing children less than two months of age to the health facility were given information and
invited to have their child enrolled if the inclusion criteria were fulfilled. Participants were enrolled over 8 months.
Trial procedures, duration and risks/benefits were painstakingly and sequentially explained to the communities,
parents and relevant relatives before and during the trial period. The proportions of participants that completed or
did not complete the trial were analyzed including the reasons for failure to complete all trial procedures.
Results: 1044 individuals received information regarding the trial of which 371 returned for screening. 300 (81%) of
them who fulfilled the inclusion criteria and did not meet any exclusion criteria were enrolled and 94% of these
completed the trial. Consent withdrawal was the main reason for not completing the trial largely (75%) due to the
father not being involved at the point of consenting or parents no longer being comfortable with blood sampling.
Conclusions: Participant retention in clinical trials remains a crucial factor in ensuring generalisability of trial data.
Appropriate measures to enhance retention should include continuous community involvement in the process,
adequate explanation of trial procedures and risks/benefits; and innovative tracing of participants adapted for the
setting.Background
Clinical trials are increasingly being conducted across
the world as new drugs, vaccines and other products
seek to enter the market. Evidence for the safety and ef-
ficacy of interventions are mainly based on the gold
standard of randomized controlled clinical trials (RCCT)
to generate credible and generalisable data, and thus
retaining the required number of subjects has become a
key issue [1,2]. Conducting such trials in sub-Saharan* Correspondence: oidoko@mrc.gm
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unless otherwise stated.Africa is however still relatively new and encumbered
with challenges.
Challenges within the region which may impact on
subject retention are numerous. As the region boasts of
a rich cultural heritage passed down from generation to
generation, myths and traditions abound which may also
have effects on new interventions and procedures. For
instance, in certain parts of West Africa blood is consid-
ered sacred and children are thought to be made ill by
blood sampling [3]. In parts of East Africa, hair is con-
sidered sacred and should not be knowingly removed.
(Personal communication) Thus clinical trials which in-
volve blood or hair sampling for analysis would likely be
met with resistance in these areas. Such factors implytd. This is an Open Access article distributed under the terms of the Creative
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gion to region. Other factors considered to negatively in-
fluence participant retention in clinical trials include
erratic health care utilization [4], low literacy levels [5],
male gender [6], older age of trial participants [7] and
psychological distress [8]. Apart from these participant
related factors, there are also investigator related bar-
riers, which could be logistic or personnel factors. A
common one is the failure to integrate the role as a care-
giver and investigator, and failure to anticipate the re-
quired work load [9]. Other barriers include the lack of
time and resources, and poor motivation of investigators.
Protocol related barriers may include, lengthy trial pe-
riods, and over burdensome visit schedule requiring a
significant degree of change in the participants’ routine
activities [10-12]. Barriers may also include the influence
of media [13,14] or community groups. In addition, there
are few established clinical trial sites in the region with
limited human resources trained in running such trials.
The few trial sites available are often overwhelmed leading
to products in queue awaiting clinical trial and thus
delayed availability of products to end users. This has led
to a need to build capacity and establish new trial sites.
Studies in adults have reported attrition rates of 24%
at 12 months and 44% at 24 months duration in longitu-
dinal studies [15]. In paediatric developmental studies
attrition rates of 10 to 15% are generally expected each
year [16]. Such high rates of attrition of trial participants
may reduce the statistical power or lead to skewed rep-
resentation of data.
The Medical research Council Unit (MRC) Unit The
Gambia has been conducting RCCTs, and had to establish
a new site at Faji Kunda Health Centre to run another trial
due to the burden on the existing site. Lessons learned
from previous sites and trials were utilized in setting up
this new site and interestingly the trial recorded a high
participant retention rate of 94% at 14 month follow up.
The culture and belief system especially related to the col-
lection of blood samples in children, and low literacy
levels were considered major factors which could likely
impact participant retention at this new site. This paper
highlights the operational lessons learnt in subject reten-
tion during the course of this trial with the hope that
other sites may learn from these and adapt where feasible.
Methods
The trial was conducted at the Faji Kunda Health Centre
that serves 7 districts within the locality in the Kombo
region of The Gambia. The staff from this centre con-
duct outreach immunization clinics to neighboring dis-
tricts. The area is peri-urban with a population of about
200,000 that are mainly subsistence farmers. This com-
munity was chosen for its close proximity to large health
facilities, relatively stable non-mobile population, andfairly large estimated population to ensure that required
sample size could be obtained.
Following ethical approval from the Gambian Government/
Medical Research Council joint Ethics Committee, the
phase II trial recruited 300 infants aged 2 to 7 months at
enrolment in two groups of 150 subjects each. Each of
these groups was further divided into three giving a total
of six sub-groups. Informed consent was obtained from
the parent/guardian of each child enrolled. The trial
started with the older group of children aged 5–7 months
at enrollment. Following review of safety data on the first
20 participants from this group, enrollment of the younger
children aged 2–3 months at enrollment commenced in
parallel (Figure 1). Participants had between 6 and 9
scheduled trial visits depending on the group to which the
participant was randomized, and involved the collection of
5 to 6 blood samples ranging from 1 to 6mls in volume per
blood draw over the trial period. All procedures were car-
ried out to International Conference on Harmonization-
Good Clinical Practice (ICH-GCP) standards.
Prior to commencement of the trial, the trial team met
with the district head (Alkalo), his cabinet, women, men
and youth leaders in order to get acceptance of the trial
from the major stakeholders in the community. At these
meetings, information regarding the trial objectives, age
of potential participants, duration of participation, ex-
pected trial procedures and risks/benefits anticipated were
highlighted. The community leaders then had opportunity
to ask questions from the trial team. Following these dis-
cussions, the intended studies were announced at the mos-
ques and churches within the community. Thereafter the
trial team carried out extensive mapping of the trial area.
This included numbering the houses, inhabitants of the
houses, enumeration of number of pregnant women, num-
ber and ages of children under one year in each household,
and situating the house within a map of the area. Potential
participants were then identified at the Health Centre at
routine infant vaccination visits and parents given informa-
tion regarding the trial from trial information sheets
(sensitization). A copy of the information sheet was then
provided to the parent to take home to read or have read
to them if illiterate, and discuss further with other decision
makers in the home (Figure 1).
Diagrams and landmarks were used in documenting
home addresses and where feasible, field assistants visited
the homes prior to enrolment to ensure that the partici-
pant could be traced. The field staff also used this oppor-
tunity to discuss details of the trial with the other parent
or other family members deemed important in the deci-
sion making process. A potential participant tracking data-
base was then set up such that each participant sensitized for
subsequent enrolment had basic details including contact
mobile phone numbers entered (Figure 1). From this database
potential trial participants were identified as they became
Figure 1 Methods utilized.
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subject follow up with an indication of the allowable time
window. These potential participants’ parents were now
approached and invited to a formal consent procedure at
which the information contained on the participant infor-
mation sheets was discussed and questions answered.
Those interested in participating in the trial then had an
assessment of consent information understanding using a
structured open ended questionnaire. This questionnaire
included an assessment of the potential participants’ par-
ents understanding that they could withdraw from the
trial at any time without adverse impact. Inability to pass
this ‘test’ (failing to answer two or more questions cor-
rectly at a maximum of two attempts) implied a lack of
understanding of the consent information and such a po-
tential participant did not proceed further [17]. Those
who passed this ‘test’ went on to sign the consent docu-
ment and proceeded to screening for eligibility to partici-
pate in the trial. Literate impartial witnesses independent
of the trial sat in on the consent process for each illiterate
potential participant to attest that all required information
was given, the potential participants’ parent had an oppor-
tunity to ask questions and apparently understood the dis-
cussion. This witness then filled in the portions of the
form to be filled by the parent, while the parent thumb
printed the form and the witness signed.
In addition each participant received an appointment
card specifying the preferred date to meet with the trial
team. This was backed up with manual tracking forms
and lists of participants due visits which could be used
should the electronic database fail. Each field assistant/
nurse was equipped with a mobile phone and top-up
funds were provided weekly depending on anticipated
follow ups, to ensure that participants could be reached
at any time as required.Each participant was questioned regarding their avail-
ability during the follow-up period, including known
short-term travel plans, and travels related to religious fes-
tivals or family events. The likelihood of moving to live
with in-laws, parents or other family members was also
explored as this is a common practice after child birth
within the area. Where possible, visits and post vaccin-
ation follow-up visits were planned around these events
and where these would interfere with follow-up or care
this was explained to the parent or legal guardian to en-
able appropriate adjustments. Potential participants un-
able or unwilling to comply were excluded at the point of
recruitment.
Previous utilization of health services in particular
immunization clinics was assessed from the infant wel-
fare record of each child. Potential participants who had
been erratic with the utilization of immunization ser-
vices were considered unlikely to comply with the trial
procedures and excluded from enrollment into the trial.
Salient information from the information sheets was rein-
forced at each clinic visit and participants given opportun-
ities to ask questions and confirm willingness to continue in
the trial. Illustrations using specimen tubes that contained
colored fluid equal to the volume of blood samples to be
collected and the fraction of this to the total blood volume
in the child were also used as previously reported [17].
The trial team met with the community again in the
middle of the trial when preliminary results were presented
on the data obtained from the mapping of the trial area
such as number of houses, households, adults, children
under one year and pregnant women. Other results shared
at these meetings included laboratory data from screening
of participants at enrollment such as community averages
for haemoglobin, liver function tests, and electrolytes con-
centrations. Individual results were discussed privately with
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tunity of these meetings to address misconceptions regard-
ing the use of blood samples and get feedback from the
community. In addition, the final outcome of the trial was
also shared with the community, at the end of the trial.
Results
1044 potential participants received information regard-
ing the trial of which 371 returned for screening.
A total of 300 participants were recruited over a
period of 8 months, with a follow up period of approxi-
mately 14 months per participant. 283 (94.3%) partici-
pants completed the trial (Figure 2). Of the 17
participants who did not complete the trial (Figure 3),
13 (75%) withdrew consent, 9 were due to family dis-
putes over continued participation where a relevant
member of the family had not been informed of the par-
ticipants’ enrolment in the trial, and 4 were due to fear of
continued blood sampling. 6 (47%) of those that withdrew
consent were after 3 or fewer visits while the remaining 7
(53%) withdrawals were after 4 or more visits. Of the
remaining 4 that did not complete the trial, 3 migrated
out of the trial area and one died.
Discussion
This trial recorded high retention rate of 94%, in a trial
that had 6–9 scheduled visits, and 5–6 blood samples
collected, within the 14 months duration of participationFigure 2 Participant flow during the trial.per enrolled participant. This was a remarkable success
story, particularly for a new trial site, likely due to mea-
sures put in place by the trial team.
The handful of participants that could not complete
the trial withdrew consent mainly due to an objection to
further participation raised by a member of the family
that was not present at the time of consent, or fear of
subsequent blood sampling. This first reason brings to
light a significant peculiarity within the region; the com-
munal nature of relationships which may affect the con-
sent process. The legal age in the Gambia is 18 years, and
parents at this age can give consent for themselves or their
children when applicable. It is clear however that in this
context, other family relationships still play a significant
role. Thus while one parent; usually the mother signs the
consent form, it is wise to have trial staff engage other
family members with a significant say in the life of the
child such as fathers, grandfathers or grandmother prior
to participant enrolment.
The use of mobile phones which has recently gained
prominence in field trials with use ranging from contact,
to education and data transmittal [18,19] is likely to have
contributed to the success of this trial. In an era where
almost every home no matter how remote can boast of a
mobile phone [20-22] it has become a resource which
the public health community, including this trial, cannot
ignore. Use in this trial was limited to contacting the
participants, but it is likely to have significantly reduced
Figure 3 Enrolment/Drop out rate.
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tention as it created an avenue to keep in close contact
with participants. Mobile phones also served to help par-
ticipants contact the trial staff whenever they had con-
cerns. This may have enhanced the confidence of the
participants as their concerns could be addressed imme-
diately without waiting for the next clinic appointment
which could have also impacted retention positively.
This coupled with the numbering of houses and avail-
ability of basic demographic data made it easy to track
participants, to address issues, perform home visits and
maintain confidence in the trial team. In a society where
living is so communal addressing concerns early was key
to ensuring that confidence in the team was maintained
within the community.
Comparable numbers withdrew during the early and
late parts in the follow up phase suggesting that dur-
ation of trial participation did not play a major role
in the decision to complete the trial. The use of a
participant tracking database also helped to ensure that
despite a complicated visit schedule varying between 6
sub-groups, participant visits were not missed. This was
particularly key considering the low literacy levels [23]
within the region where very few participants would re-
turn on the basis of an appointment alone. This also
helped the trial team to plan workload in terms of re-
sources needed weekly within the field. Such planning
minimized participant waiting time which may have also
contributed to the high retention rates. The prior mapping
of the community and use of diagrams to identify
homes ensured that despite the lack of an address
system in the locality the trial team was able to trace
participants, thus minimizing drop-outs due to inability
to trace participants.
Screening out participants with parents/guardians per-
ceived to be unable to comply with the protocol could alsohave played a role. This included ensuring that criteria
such as presence within the trial area throughout the trial
duration, including planned short term/long term travel,
and previous utilization of immunization services were
fulfilled.
Blood sampling remains a major challenge in conduct-
ing clinical trials in West Africa, with more resistance
often encountered when larger blood volumes are col-
lected [3,24]. This factor also came to bear in this trial
being the only other reason for consent withdrawal, with
some subjects who completed the trial declining blood
sampling while accepting safety review. Constant educa-
tion including the use of illustrations is likely to have
minimized this effect. Important to note however is the
spread of information within communities often fuelled
by communal living. At some point in this trial, the trial
team became aware that rumors were circulating in the
community that blood samples from trials were sold in
Europe for monetary gain. Community engagement through
community meetings, sharing preliminary demographic
and clinical laboratory results with the community as well
as taking representatives of the community to witness
the laboratory processing of the blood samples helped
to dispel such rumors. This was likely further strength-
ened by the involvement of community leaders in the
community engagement sessions. The involvement of
these leaders was crucial to gaining community accept-
ance of the trial which is crucial in these settings. Key and
opinion leaders have been documented to play a signifi-
cant role in acceptance of public health interventions
[25,26]. Following trial completion, feedback on results
has also been given to the community. These meetings
were useful for both the trial team and the community
in particular as that was the first time these parame-
ters were known to them. This will likely also have a
positive impact on future trials.
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Participant retention in clinical trials remains a crucial
factor in ensuring generalisabilty of trial data. This trial with
retention of 94.3% in a trial in which a participant remained
for 14 months, with rigorous scheduled visits and blood
sampling is a huge success. This excellent retention can be
ascribed mainly to continuous community involvement, ad-
equate explanation of trial procedures, risks/benefits, and
innovative tracing of participants adapted for the setting.
It is hoped that these will guide others developing new
trial sites or reviewing the operations at existing sites.
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